

MANNKIND CORP  
Form 8-K  
December 23, 2004

**Table of Contents**

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 22, 2004

**MannKind Corporation**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**000-50865**  
(Commission File Number)

**13-3607736**  
(IRS Employer  
Identification No.)

**28903 North Avenue Paine**  
**Valencia, California**  
(Address of principal executive offices)

**91355**  
(Zip Code)

Registrant's Telephone Number, Including Area Code: **(661) 775-5300**

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

---

**TABLE OF CONTENTS**

Item 8.01 Other Events

Item 9.01 Financial Statements and Exhibits

SIGNATURE

EXHIBIT INDEX

Exhibit 99.1

---

**Table of Contents**

**Section 8 Other Events**

**Item 8.01 Other Events**

On December 22, 2004, MannKind Corporation issued a press release announcing results from its US-based late phase 2 clinical study of Technosphere<sup>®</sup> Insulin. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

**Section 9 Financial Statements and Exhibits**

**Item 9.01 Financial Statements and Exhibits**

(c) Exhibits.

Number	Description
99.1	Press Release of MannKind Corporation dated December 22, 2004, reporting MannKind's results from its US-based late phase 2 clinical study of Technosphere <sup>®</sup> Insulin.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MANNKIND CORPORATION**

By: /s/ Richard L. Anderson  
Name: Richard L. Anderson  
Title: Chief Financial Officer

Dated: December 22, 2004

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Number</b>	<b>Description</b>
99.1	Press Release of MannKind Corporation dated December 22, 2004, reporting MannKind's results from its US-based late phase 2 clinical study of Technosphere <sup>®</sup> Insulin.